Discontinuation Rate of Newly Prescribed Donepezil in Alzheimer's Disease Patients in Asia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박기형 | - |
dc.contributor.author | 양영순 | - |
dc.contributor.author | Chen Christopher | - |
dc.contributor.author | 심용수 | - |
dc.contributor.author | Domingueze Jacqueline C. | - |
dc.contributor.author | 이찬녕 | - |
dc.contributor.author | 강경훈 | - |
dc.contributor.author | 김희진 | - |
dc.contributor.author | 정슬기 | - |
dc.contributor.author | 정지향 | - |
dc.contributor.author | Hong Zhen | - |
dc.contributor.author | 윤수진 | - |
dc.contributor.author | Zhang Zhen-Xin | - |
dc.contributor.author | 김은주 | - |
dc.contributor.author | 장재원 | - |
dc.contributor.author | Li Yansheng | - |
dc.contributor.author | Xu Yun | - |
dc.contributor.author | Lin Yu-Te | - |
dc.contributor.author | Qu Qiumin | - |
dc.contributor.author | Hu Chaur-Jong | - |
dc.contributor.author | Chou Chih-Ho | - |
dc.contributor.author | Fan Dongsheng | - |
dc.contributor.author | Kandiah Nagaendran | - |
dc.contributor.author | Yang Yuan-Han | - |
dc.contributor.author | Lau Chi-ieong | - |
dc.contributor.author | Chu Leung-Wing | - |
dc.contributor.author | Wang Huali | - |
dc.contributor.author | 정산 | - |
dc.contributor.author | 최성혜 | - |
dc.contributor.author | 김상윤 | - |
dc.date.accessioned | 2021-08-27T02:40:51Z | - |
dc.date.available | 2021-08-27T02:40:51Z | - |
dc.date.created | 2021-07-03 | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 1738-6586 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/81936 | - |
dc.description.abstract | Background and Purpose The rate of donepezil discontinuation and the underlying reasons for discontinuation in Asian patients with Alzheimer’s disease (AD) are currently unknown. We aimed to determine the treatment discontinuation rates in AD patients who had newly been prescribed donepezil in routine clinical practice in Asia. Methods This 1-year observational study involved 38 institutions in seven Asian countries, and it evaluated 398 participants aged 50–90 years with a diagnosis of probable AD and on newly prescribed donepezil monotherapy. The primary endpoint was the rate of donepezil discontinuation over 1 year. Secondary endpoints included the reason for discontinuation, treatment duration, changes in cognitive function over the 1-year study period, and compliance as assessed using a clinician rating scale (CRS) and visual analog scale (VAS). Results Donepezil was discontinued in 83 (20.9%) patients, most commonly due to an adverse event (43.4%). The mean treatment duration was 103.67 days in patients who discontinued. Among patients whose cognitive function was assessed at baseline and 1 year, there were no significant changes in scores on the Mini-Mental State Examination, Montreal Cognitive Assessment, and Trail-Making Test–Black and White scores, whereas the Clinical Dementia Rating score increased significantly (p<0.001). Treatment compliance at 1 year was 96.8% (306/316) on the CRS and 92.6±14.1% (mean±standard deviation) on the VAS. Conclusions In patients on newly prescribed donepezil, the primary reason for discontinuation was an adverse event. Cognitive assessments revealed no significant worsening at 1 year, indicating that continuous donepezil treatment contributes to the maintenance of cognitive function. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한신경과학회 | - |
dc.relation.isPartOf | Journal of Clinical Neurology | - |
dc.title | Discontinuation Rate of Newly Prescribed Donepezil in Alzheimer's Disease Patients in Asia | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000681679300006 | - |
dc.identifier.doi | 10.3988/jcn.2021.17.3.376 | - |
dc.identifier.bibliographicCitation | Journal of Clinical Neurology, v.17, no.3, pp.376 - 384 | - |
dc.identifier.kciid | ART002733521 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85109400706 | - |
dc.citation.endPage | 384 | - |
dc.citation.startPage | 376 | - |
dc.citation.title | Journal of Clinical Neurology | - |
dc.citation.volume | 17 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | 박기형 | - |
dc.subject.keywordAuthor | mer’s disease | - |
dc.subject.keywordAuthor | Asia | - |
dc.subject.keywordAuthor | cognition | - |
dc.subject.keywordAuthor | donepezil. | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.